Fluorescent fusion polypeptide, biosensor comprising said polypeptide and uses thereof

ABSTRACT

The present invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein:
         a. the membrane localization peptide is located at the N-terminus of the fluorescent fusion polypeptide and is physically bound, optionally through a linker, to the fluorescent peptide, which in turn is physically bound, optionally through a linker, to the second messenger transduction protein binding peptide; and   b. the second messenger transduction protein binding peptide is physically bound, optionally through a linker, to the reticulum retention signal, which in turn is located at the C-terminus of the fluorescent fusion polypeptide.

RELATED APPLICATIONS

This application is a divisional application of U.S. application Ser. No. 14/412,513, filed on Jan. 2, 2015; which is a 35 U.S.C. §371 national stage filing of International Application No. PCT/EP2013/064400, filed on Jul. 8, 2013; which claims priority to European Patent Application No. 12382272.8, filed on Jul. 6, 2012. The entire contents of each of the foregoing applications are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention pertains to the biotechnological field, particularly to a fluorescent fusion polypeptide, a biosensor comprising said polypeptide and uses thereof.

BACKGROUND OF THE INVENTION

The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention, and is not admitted to describe or constitute prior art to the present invention.

High-content screening (HCS) in cell-based systems uses living cells as tools in biological research to elucidate the workings of normal and diseased cells. HCS is also used to discover and optimizes new drug candidates.

High content screening is a combination of modern cell biology, with all its molecular tools, with automated high resolution microscopy and robotic handling. Cells are first exposed to chemicals or RNAi reagents. Changes in cell morphology are then detected using image analysis. Changes in the amounts of proteins synthesized by cells are measured using a variety of techniques such as the green fluorescent proteins fused to endogenous proteins, or by fluorescent antibodies.

At a cellular level, parallel acquisition of data on different cell properties, for example activity of signal transduction cascades and cytoskeleton integrity is the main advantage of this method in comparison to the faster but less detailed high throughput screening. While HCS is slower, the wealth of acquired data allows a more profound understanding of drug effects. In this sense, one of the goals of HCS in the acquisition of data in connection to the activity of signal transduction cascades is to determine the effect of different drugs in the signalling processes through the measurement of intracellular second messenger levels.

Second messengers are molecules that relay signals from receptors on the cell surface to target molecules inside the cell, in the cytoplasm or nucleus. They relay the signals of hormones like epinephrine (adrenaline), growth factors, and others, and cause some kind of change in the activity of the cell. They greatly amplify the strength of the signal. Secondary messengers are a component of signal transduction cascades. Among these second messengers, the cAMP and calcium provide the paradigm for the second messenger concept and are appreciated as ubiquitous and critical intracellular molecules that regulate many key processes in the cell.

Ideally, said measurement requires tools of precise localization, high dynamic range and as little disturbance of cell physiology as possible that in turn are capable of monitoring the levels of second messengers in vivo by using a high content screening method.

For this, various fluorescent biosensors based on dynamically changing the fluorescent properties have been generated. In this sense, these types of biosensors are often based on a change in Fluorescent Resonance Energy Transfer (FRET). FRET is the process by which energy from an excited donor fluorophore is transferred to an acceptor fluorophore through radiationless dipole-dipole coupling. The efficiency of this energy transfer is highly dependent on the distance between (e.g. <10 nm for CFP/YFP) and the relative orientation of donor and acceptor fluorophore. However, FRET-based biosensors in the context of high content screening methods requires of a detection equipment of at least four filters, two for the excitation and two for the emission. In addition, due to the low intensity of the detection signal, the detection signal range and the screening sensibility are low. Lastly, the use of more than one fluorescence emission signal requires the use of more algorithms in order to correctly analyse the final signal.

Thus, there is still a need to develop improved methods or products for real time measurement of second messenger concentration within the dynamic environment of the living cell.

BRIEF DESCRIPTION OF THE INVENTION

A first aspect of the present invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In another preferred embodiment of the first aspect of the invention, the membrane localization peptide is the extracellular domain of interleukin-2 receptor of SEQ ID No 17 or a variant which is at least 90% homologous to this sequence over the entire region based on amino acid identity and the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL.

In a more preferred embodiment of the first aspect of the invention, said second messenger transduction protein binding peptide is a cAMP transduction protein binding peptide, a calcium transduction protein binding peptide, an IP3 transduction protein binding peptide, a cGMP transduction protein binding peptide or a diacylglycerol transduction protein binding peptide. Thus in a further preferred embodiment of the invention, the fluorescent fusion polypeptide of the first aspect of the invention is capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of a second messenger selected from the list consisting of calcium, cAMP, IP3, cGMP or diacyglycerol.

A second aspect of the invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of intracellular calcium, comprising a membrane localization peptide, a second messenger transduction protein binding peptide comprising a calmodulin binding sequence, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide comprising the calmodulin         binding sequence; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In a preferred embodiment of the second aspect of the invention, the calmodulin binding sequence is selected from the list consisting of SEQ ID No 1 (MEKRRWKKNFIAVSAANRFKKISSSGAL), SEQ ID No 2 (ASPWKSARLMVHTVATFNSI), SEQ ID No 3 (AIGFKKLAEAVKFSAKLMGQ), SEQ ID No 4 (KKTFKEVANAVKISASLMGT), SEQ ID No 5 (GAVLKVLTTGLPALISWIKR), SEQ ID No 6 (RGGFRRIARLVGVLREWAYR), SEQ ID No 7 (GGRLALLRARLKELAALEAA) and SEQ ID No 8 (AEGVRNIKSMWEKGNVFSSP) or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In a further preferred embodiment of the second aspect of the invention, the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL and/or the membrane localization peptide is the extracellular domain of interleukin-2 of SEQ ID No 17 or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In another preferred embodiment of the second aspect of the invention the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.

In a still further preferred embodiment of the second aspect of the invention:

-   -   a. the calmodulin binding sequence is selected from the list         consisting of SEQ ID No 1 (MEKRRWKKNFIAVSAANRFKKISSSGAL), SEQ ID         No 2 (ASPWKSARLMVHTVATFNSI), SEQ ID No 3 (AIGFKKLAEAVKFSAKLMGQ),         SEQ ID No 4 (KKTFKEVANAVKISASLMGT), SEQ ID No 5         (GAVLKVLTTGLPALISWIKR), SEQ ID No 6 (RGGFRRIARLVGVLREWAYR), SEQ         ID No 7 (GGRLALLRARLKELAALEAA) and SEQ ID No 8         (AEGVRNIKSMWEKGNVFSSP) or a variant which is at least 90%         homologous to any of these sequences over the entire region         based on amino acid identity;     -   b. the membrane localization peptide is the extracellular domain         of interleukin-2 receptor of SEQ ID No 17 or a variant which is         at least 90% homologous to this sequence over the entire region         based on amino acid identity; and     -   c. the reticulum retention signal is a peptide selected from the         following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR,         wherein X is any aminoacid and wherein preferably said reticulum         retention signal is KDEL.

In a still other preferred embodiment of the invention, the calcium fluorescent fusion polypeptide comprises or preferably consists of SEQ ID No 15.

A third aspect of the invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of intracellular cAMP, comprising a membrane localization peptide, a second messenger transduction protein binding peptide comprising a binding sequence to the RI and RII regulatory domains of PKA, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In a preferred embodiment of the third aspect of the invention, the binding sequence to the RI and RII regulatory domains of PKA is selected from the list consisting of SEQ ID No 9 (DLIEEAASRIVDAVIEQVKAAGAY), SEQ ID no 10 (VQGNTDEAQEELAWKIAKMIVSDVMQQ), SEQ ID No 11 (VQGNTDEAQEELLWKIAKMIVSDVMQQ), SEQ ID No 12 (FEELAWKIAKMIWSDVFQQ), SEQ ID No 13 (QIEYLAKQIVDNAIQQAK) and SEQ ID No 14 (LEQYANQLADQIIKEATE) or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In a further preferred embodiment of the third aspect of the invention, the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL and/or the membrane localization peptide is the extracellular domain of interleukin-2 of SEQ ID No 17 or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In another preferred embodiment of the third aspect of the invention, the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.

In a still further preferred embodiment of the third aspect of the invention:

-   -   a. the binding sequence to the RI and RII regulatory domains of         PKA is selected from the list consisting of SEQ ID No 9         (DLIEEAASRIVDAVIEQVKAAGAY), SEQ ID no 10         (VQGNTDEAQEELAWKIAKMIVSDVMQQ), SEQ ID No 11         (VQGNTDEAQEELLWKIAKMIVSDVMQQ), SEQ ID No 12         (FEELAWKIAKMIWSDVFQQ), SEQ ID No 13 (QIEYLAKQIVDNAIQQAK) and SEQ         ID No 14 (LEQYANQLADQIIKEATE) or a variant which is at least 90%         homologous to any of these sequences over the entire region         based on amino acid identity;     -   b. the membrane localization peptide is the extracellular domain         of interleukin-2 receptor of SEQ ID No 17 or a variant which is         at least 90% homologous to this sequence over the entire region         based on amino acid identity; and     -   c. the reticulum retention signal is a peptide selected from the         following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR,         wherein X is any aminoacid and wherein preferably the reticulum         retention signal is KDEL.

In still another preferred embodiment of the third aspect of the invention, the fluorescent fusion polypeptide comprises or preferably consists of SEQ ID No 16.

A fourth aspect of the invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of intracellular diacylglycerol, comprising a membrane localization peptide, a second messenger transduction protein binding peptide comprising a binding sequence to PKCδ, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In a preferred embodiment of the fourth aspect of the invention, the binding sequence to PKCδ is SEQ ID No 19 (AARKRKGSFFYGG), or a variant which is at least 90% homologous to this sequence over the entire region based on amino acid identity.

In a further preferred embodiment of the fourth aspect of the invention, the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL and/or the membrane localization peptide is the extracellular domain of interleukin-2 of SEQ ID No 17 or a variant which is at least 90% homologous to this sequence over the entire region based on amino acid identity.

In another preferred embodiment of the fourth aspect of the invention, the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.

In a still further preferred embodiment of the fourth aspect of the invention:

-   -   a. the binding sequence to PKCδ is SEQ ID No 19 (AARKRKGSFFYGG),         or a variant which is at least 90% homologous to this sequence         over the entire region based on amino acid identity;     -   b. the membrane localization peptide is the extracellular domain         of interleukin-2 receptor of SEQ ID No 17 or a variant which is         at least 90% homologous to this sequence over the entire region         based on amino acid identity; and     -   c. the reticulum retention signal is a peptide selected from the         following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR,         wherein X is any aminoacid and wherein preferably the reticulum         retention signal is KDEL.

In still another preferred embodiment of the fourth aspect of the invention, the fluorescent fusion polypeptide comprises SEQ ID No 18.

A fifth aspect of the invention refers to a nucleic acid molecule comprising a polynucleotide sequence coding for a polypeptide as defined in any of the previous aspects of the invention.

A sixth aspect of the invention refers to a biosensor comprising the fusion polypeptide as defined in the first, second, third and fourth aspects of the invention.

A seventh aspect of the invention refers to a cell comprising the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or the biosensor as defined in the sixth aspect of the invention, wherein preferably said cell is cell line U2O2.

In a further aspect, the present invention relates to several uses for the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or of the biosensor as defined in the sixth aspect of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments and together with the description illustrate the disclosed compositions and methods.

FIG. 1. Schematic representation of the fluorescent biosensor cellular localization model. Fluorescent biosensor changes its localization within the cell from the cell cytoplasmic membrane to the vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm.

FIG. 2. Second messenger determination using the fluorescent biosensor. Increase in the second messenger concentration promotes a redistribution of the fluorescent biosensor. The change in the cellular fluorescence was calculated as an increment of the granularity of these cells. These same results were obtained with three different clones of the above cell lines as illustrated in this figure which provides proof of the reproducibility of these results corresponding to three clones containing the calcium biosensor (left graphic) or three clones containing the cAMP biosensor (right graphic).

FIG. 3. Cellular distribution of calcium biosensor stimulated cells. U2OS, stably expressing human Neurokinin receptor 1 and fluorescent calcium biosensor, were stimulated with 10 uM of Substancia P agonist during 6 hours. After the treatment, the fluorescent biosensor was internalized in vesicles in the citosol. Human Neurikinin receptor 1 activity was determined measuring the generation of the vesicle using image analysis algorithms.

FIG. 4. Concentration response curve for Substancia P in Neurokinin 1 receptor -calcium biosensor cell line. Cells were treated with 10 log dilution series (n=4). The Ec50 for the Subtancia P was ^(˜)9.5×10⁻¹² M after a treatment of 6 h with agonist. Cells were fixed and the nuclei were stained with DAPI. % Activity was calculated relative to positive (10 uM). The internalization assay was validated with an average of Z′=0.85+/−0.01 for High Content Screening.

FIG. 5. Cellular distribution of cAMP biosensor stimulated cells. U2OS stably expressing human Adrenergic beta 2 receptor and fluorescent cAMP biosensor, were stimulated with 10 uM of Isoproterenol agonist during 36 hours. After the treatment, the fluorescent biosensor was internalized in vesicles in the citosol. Human Adrenergic beta 2 receptor activity was determined measuring the generation of the vesicle using image analysis algorithms.

FIG. 6. Concentration response curve for Isoproterenol in Adrenergic beta 2 -cAMP biosensor cell line. Cells were treated with 6 log dilution series (n=4). The Ec50 for the Isoproterenol was 2.3×10⁻⁷ M after a treatment of 36 h with agonist. Cells were fixed and the nuclei were stained with DAPI. % Activity was calculated relative to positive (10 uM). The internalization assay was validated with an average of Z′=0.7+/−0.01 for High Content Screening.

FIG. 7. Cellular distribution of DAG biosensor stimulated cells. U2OS stably expressing fluorescent DAG biosensor, were stimulated with 25 ng/ml of PMA during 4 hours. After the treatment, the fluorescent biosensor was internalized in vesicles in the citosol. DAG biosensor activity was determined measuring the generation of the vesicle using image analysis algorithms.

FIG. 8. Concentration response curve for DAG biosensor cell line. Cells were treated with 9 log dilution series (n=4). The Ec50 for the Isoproterenol was 2.89×10⁻⁴ ng/ml after a treatment of 4 h with DAG. Cells were fixed and the nuclei were stained with DAPI. % Activity was calculated relative to positive (50 ng/ml). The internalization assay was validated with an average of Z′=0.76+/−0.01 for High Content Screening.

DESCRIPTION OF THE INVENTION

Unless expressly specified otherwise, the term “comprising” is used in the context of the present document to indicate that further members may optionally be present in addition to the members of the list introduced by “comprising”. It is, however, contemplated as a specific embodiment of the present invention that the term “comprising” encompasses the possibility of no further members being present, i.e. for the purpose of this embodiment “comprising” is to be understood as having the meaning of “consisting of”.

Definitions

In the context of the present invention, the term “fusion polypeptide” refers to a hybrid polypeptide comprising a combination of at least four peptides from different proteins that are combined into the same polypeptide structure.

In the context of the present invention, the term “membrane localization peptide” is intended to mean a peptide whose natural intracellular localization is in the plasma membrane.

As used herein, the term “transduction protein binding peptide” is intended to mean a peptide that is able to bind a transduction protein in a specific conformation. Therefore, this peptide is able to bind the transduction protein only when this transduction protein is interacting with a second messenger (cAMP, Ca2+, IP3, cGMP, diacylglycerol . . . ).

As used herein, the term “reticulum retention signal” is intended to mean a short peptide chain that directs the transport of the polypeptide to the endoplasmic reticulum and through the secretory pathway conferring thereby a multivesicular localization.

As used herein, the term “fluorescent peptide” is intended to mean a fluorescent peptide that has fluorescent capacities. Fluorescent peptide domains are characterized by having a specific excitation spectrum and emission spectrum.

In the context of the present invention, the linker has at least one amino acid residue, preferably at least two consecutive amino acid residues.

As used herein, the term “biosensor” is intended to mean a molecular tool or entity that is sensitive to, and can respond to, a physical or chemical stimulus and transmit information about cellular status.

As used herein, the term “drug” is intended to mean a molecule that potentially acts as an agonist or antagonist or modulator of a signalling pathway.

As used herein “stable cell line” is intended to mean a cell line that has been transfected or infected with a foreign piece of DNA that has incorporated itself into the genome of the cell.

As used herein “calmodulin binding sequence” is intended to mean the amino acid sequence corresponding to the calmodulin binding domain of the skeletal muscle myosin light chain kinase. This sequence is included in the basic 1-8-14 subclass of the 1-14 calmodulin binding motif. The consensus sequence of the basic 1-8-14 is (RK)(RK)(RK)(FILVW)xxxxxx(FAILVW)xxxxx(FILVW). These types of sequences can easily be found in the Calmodulin Binding Database (http://calcium.uhnres.utoronto.ca/ctdb/ctdb/home.html).

As used herein “binding sequence to the RI and RII regulatory domains of PKA” is intended to mean the conserved amino acid sequence that is present in A-kinase anchor protein family (AKAP) and whose principal function is binding to the regulatory domain (RI or RII) of protein kinase A (PKA).

As used herein “HT31” is the peptide derived from human thyroid A-kinase anchoring protein (AKAP) that can destroy the anchorage of A-kinase (after activation by cAMP signal) by competing with AKAPs. HT31 binds to the two regulatory domains (RI and RII) of Protein Kinase A but its affinity for these domains is different: low for RI domain and high for RII domain.

As used herein “binding sequence to PKCdelta” is intended to mean the amino acid sequence corresponding to a synthetic soluble peptide which binds specifically to PKCdelta and no other PKCs. These types of sequences can be easily found in PKCLab Database (http://www.pkclab.org/PKC/link/substrate_specificity.htm).

DETAILED DESCRIPTION OF THE INVENTION

The present invention confronts the problem of providing tools of precise localization, high dynamic range and as little disturbance of cell physiology as possible that are capable of monitoring a variation in the intracellular concentration levels of second messengers in vivo by using High-content screening (HCS) in cell-based systems, wherein these tools do not have the disadvantages of FRET-based biosensors.

In order to solve the above problem, the authors of the present invention designed a new fluorescent fusion polypeptide comprising a membrane localization peptide, a fluorescent peptide, a second messenger transduction protein binding peptide and a reticulum retention signal. This biosensor is formed by two peptides targeted to two different cellular compartments, allowing the measurement of the second messenger concentration by monitoring the distribution of the fluorescent polypeptide within the cellular cytoplasm. In this sense, the biosensor translocation within the cell shall be due to a change in its 3D conformation that hides or exposes the location signals in both ends of the polypeptide triggered by the binding of the transduction protein to the second messenger transduction protein binding peptide. In the basal state, the biosensor is located in one of the compartments; this means that the location peptide directed to the other cellular compartment is hidden by the 3D conformation. When the concentration of the second messenger is increased due to a cellular stimulation, these second messengers bind to the transduction protein that becomes active. The active transduction protein is able to bind to the transduction protein binding peptide in the biosensor causing a conformational change. At this point the spatial distribution of the different structural elements in the biosensor is modified and the location peptide directed to the other cellular compartment is exposed by the new 3D conformation so that the whole biosensor is transported to its new location at the new cellular compartment. All this process can be traced in living cells due to the presence of the fluorescent protein in the biosensor. A schematic view of the process can be visualized in the schematic representation shown in FIG. 1.

However, the authors of the present invention realized that the order of the peptides within the above mentioned fluorescent fusion polypeptide could not be placed arbitrarily within the polypeptide. This is the case since after numerous experiments the authors concluded that only one combination of elements provided the technical effect of transporting the biosensor to the other cellular compartment, such combination was:

-   -   a. the membrane localization peptide must be located at the         N-terminus of the fluorescent fusion polypeptide and must be         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn must be physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide         must be physically bound, optionally through a linker, to the         reticulum retention signal, which in turn must be located at the         C-terminus of the fluorescent fusion polypeptide.

The authors tested whether such biosensor having the above structure could be employ for detecting and quantifying different types of second messengers. As illustrated in examples 1-3 disclosed herein, the authors of the present invention constructed three different fluorescent fusion polypeptides, all of them comprising the extracellular domain of interleukin-2 receptor of SEQ ID No 17 as the membrane localization peptide, the peptide KDEL as the reticulum retention signal and the turboGFP as the fluorescent peptide. Thus, the only difference between these fluorescent fusion polypeptides lied on the type of second messenger transduction protein binding peptide used. In this sense, in the case of the calcium biosensor of example 1 the authors used a second messenger transduction protein binding peptide comprising a calmodulin binding domain, in the case of the cAMP biosensor of example 2 the authors used a second messenger transduction protein binding peptide comprising a protein kinase A (PKA) binding domain from A-kinase anchor protein (AKAP) and in the case of the diacylglycerol biosensor of example 3 the authors used a second messenger transduction protein binding peptide comprising the binding domain of SEQ ID No 19.

Surprisingly, the results shown in the examples and drawings presented herein by using the above fusion polypeptides of examples 1-3 indicated that an increased in the concentration of the second messenger induced a conformational change in the biosensor which promoted a redistribution of the fluorescent biosensor. The activity was calculated in all three cases as an increment of the granularity of the cells transfected with the biosensors of the invention. The fluorescence redistribution of the biosensor was detected by fluorescence using image analysis algorithms. Consequently, the variations in the second messenger concentrations can be monitored through this “hiding and exposition” process of location signals and the final localization of the biosensor.

Thus, a first aspect of the present invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In another preferred embodiment of the first aspect of the invention, the membrane localization peptide is the extracellular domain of interleukin-2 receptor of SEQ ID No 17 or a variant which is at least 90% homologous to this sequence over the entire region based on amino acid identity and the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL.

In a more preferred embodiment of the first aspect of the invention, said second messenger transduction protein binding peptide is a cAMP transduction protein binding peptide, a calcium transduction protein binding peptide, an IP3 transduction protein binding peptide, a cGMP transduction protein binding peptide or a diacylglycerol transduction protein binding peptide. Thus in a further preferred embodiment of the invention, the fluorescent fusion polypeptide of the first aspect of the invention is capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of a second messenger selected from the list consisting of calcium, cAMP, IP3, cGMP or diacyglycerol.

A second aspect of the invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of intracellular calcium, comprising a membrane localization peptide, a second messenger transduction protein binding peptide comprising a calmodulin binding sequence, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide comprising the calmodulin         binding sequence; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In a preferred embodiment of the second aspect of the invention, the calmodulin binding sequence is selected from the list consisting of SEQ ID No 1 (MEKRRWKKNFIAVSAANRFKKISSSGAL), SEQ ID No 2 (ASPWKSARLMVHTVATFNSI), SEQ ID No 3 (AIGFKKLAEAVKFSAKLMGQ), SEQ ID No 4 (KKTFKEVANAVKISASLMGT), SEQ ID No 5 (GAVLKVLTTGLPALISWIKR), SEQ ID No 6 (RGGFRRIARLVGVLREWAYR), SEQ ID No 7 (GGRLALLRARLKELAALEAA) and SEQ ID No 8 (AEGVRNIKSMWEKGNVFSSP) or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In a further preferred embodiment of the second aspect of the invention, the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL and/or the membrane localization peptide is the extracellular domain of interleukin-2 of SEQ ID No 17 or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In another preferred embodiment of the second aspect of the invention the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.

In a still further preferred embodiment of the second aspect of the invention:

-   -   a. the calmodulin binding sequence is selected from the list         consisting of SEQ ID No 1 (MEKRRWKKNFIAVSAANRFKKISSSGAL), SEQ ID         No 2 (ASPWKSARLMVHTVATFNSI), SEQ ID No 3 (AIGFKKLAEAVKFSAKLMGQ),         SEQ ID No 4 (KKTFKEVANAVKISASLMGT), SEQ ID No 5         (GAVLKVLTTGLPALISWIKR), SEQ ID No 6 (RGGFRRIARLVGVLREWAYR), SEQ         ID No 7 (GGRLALLRARLKELAALEAA) and SEQ ID No 8         (AEGVRNIKSMWEKGNVFSSP) or a variant which is at least 90%         homologous to any of these sequences over the entire region         based on amino acid identity;     -   b. the membrane localization peptide is the extracellular domain         of interleukin-2 receptor of SEQ ID No 17 or a variant which is         at least 90% homologous to this sequence over the entire region         based on amino acid identity; and     -   c. the reticulum retention signal is a peptide selected from the         following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR,         wherein X is any aminoacid and wherein preferably said reticulum         retention signal is KDEL.

In a still other preferred embodiment of the invention, the fluorescent fusion polypeptide comprises or preferably consists of SEQ ID No 15.

A third aspect of the invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of intracellular cAMP, comprising a membrane localization peptide, a second messenger transduction protein binding peptide comprising a binding sequence to the RI and RII regulatory domains of PKA, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In a preferred embodiment of the third aspect of the invention, the binding sequence to the RI and RII regulatory domains of PKA is selected from the list consisting of SEQ ID No 9 (DLIEEAASRIVDAVIEQVKAAGAY), SEQ ID no 10 (VQGNTDEAQEELAWKIAKMIVSDVMQQ), SEQ ID No 11 (VQGNTDEAQEELLWKIAKMIVSDVMQQ), SEQ ID No 12 (FEELAWKIAKMIWSDVFQQ), SEQ ID No 13 (QIEYLAKQIVDNAIQQAK) and SEQ ID No 14 (LEQYANQLADQIIKEATE) or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In a further preferred embodiment of the third aspect of the invention, the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any aminoacid and wherein preferably said reticulum retention signal is KDEL and/or the membrane localization peptide is the extracellular domain of interleukin-2 of SEQ ID No 17 or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In another preferred embodiment of the third aspect of the invention, the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.

In a still further preferred embodiment of the third aspect of the invention:

-   -   a. the binding sequence to the RI and RII regulatory domains of         PKA is selected from the list consisting of SEQ ID No 9         (DLIEEAASRIVDAVIEQVKAAGAY), SEQ ID no 10         (VQGNTDEAQEELAWKIAKMIVSDVMQQ), SEQ ID No 11         (VQGNTDEAQEELLWKIAKMIVSDVMQQ), SEQ ID No 12         (FEELAWKIAKMIWSDVFQQ), SEQ ID No 13 (QIEYLAKQIVDNAIQQAK) and SEQ         ID No 14 (LEQYANQLADQIIKEATE) or a variant which is at least 90%         homologous to any of these sequences over the entire region         based on amino acid identity;     -   b. the membrane localization peptide is the extracellular domain         of interleukin-2 receptor of SEQ ID No 17 or a variant which is         at least 90% homologous to this sequence over the entire region         based on amino acid identity; and     -   c. the reticulum retention signal is a peptide selected from the         following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR,         wherein X is any aminoacid and wherein preferably the reticulum         retention signal is KDEL.

In still another preferred embodiment of the third aspect of the invention, the fluorescent fusion polypeptide comprises or preferably consists of SEQ ID No 16.

A fourth aspect of the invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of intracellular diacylglycerol, comprising a membrane localization peptide, a second messenger transduction protein binding peptide comprising a binding sequence to PKCδ, a reticulum retention signal and a fluorescent peptide wherein:

-   -   a. the membrane localization peptide is located at the         N-terminus of the fluorescent fusion polypeptide and is         physically bound, optionally through a linker, to the         fluorescent peptide, which in turn is physically bound,         optionally through a linker, to the second messenger         transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide is         physically bound, optionally through a linker, to the reticulum         retention signal, which in turn is located at the C-terminus of         the fluorescent fusion polypeptide.

In a preferred embodiment of the fourth aspect of the invention, the binding sequence to PKCδ is SEQ ID No 19 (AARKRKGSFFYGG), or a variant which is at least 90% homologous to this sequence over the entire region based on amino acid identity.

In a further preferred embodiment of the fourth aspect of the invention, the reticulum retention signal is a peptide selected from the following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR wherein x is any aminoacid and wherein preferably said reticulum retention signal is KDEL and/or the membrane localization peptide is the extracellular domain of interleukin-2 of SEQ ID No 17 or a variant which is at least 90% homologous to any of these sequences over the entire region based on amino acid identity.

In another preferred embodiment of the fourth aspect of the invention, the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.

In a still further preferred embodiment of the fourth aspect of the invention:

-   -   a. the binding sequence to PKCδ is SEQ ID No 19 (AARKRKGSFFYGG),         or a variant which is at least 90% homologous to this sequence         over the entire region based on amino acid identity;     -   b. the membrane localization peptide is the extracellular domain         of interleukin-2 receptor of SEQ ID No 17 or a variant which is         at least 90% homologous to this sequence over the entire region         based on amino acid identity; and     -   c. the reticulum retention signal is a peptide selected from the         following list consisting of KDEL, HDEL, KKXX, KXKXX and RXR,         wherein X is any aminoacid and wherein preferably the reticulum         retention signal is KDEL.

In still another preferred embodiment of the fourth aspect of the invention, the fluorescent fusion polypeptide comprises SEQ ID No 18.

A fifth aspect of the invention refers to a nucleic acid molecule comprising a polynucleotide sequence coding for a polypeptide as defined in any of the previous aspects of the invention.

A sixth aspect of the invention refers to a biosensor comprising the fusion polypeptide as defined in the first, second, third and fourth aspects of the invention.

A seventh aspect of the invention refers to a cell comprising the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or the biosensor as defined in the sixth aspect of the invention, wherein preferably said cell is cell line U2O2.

In a further aspect, the present invention relates to several uses for the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or of the biosensor as defined in the sixth aspect of the invention. A first use of the biosensor according to the present invention is for detecting and quantifying second messengers including, but not limited thereto, cAMP, calcium, diacylglycerol, IP3 and cGMP. As already stated, binding of the second messenger to the fluorescent fusion polypeptide of any of the aspects of this invention results in a substantial change in the spatial conformation that leads to a change in the intracellular fluorescence localization. This fluorescence translocation can be harnessed for second messenger quantification by fluorescence microscopy. In addition, all this process can be traced in living cells due to the presence of the fluorescent protein in the biosensor.

The employment of the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or the biosensor as defined in the sixth aspect of the invention further involves its use as a tool for drug screening.

In addition, the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or the biosensor as defined in the sixth aspect of the invention is useful in the practice of essentially any application for which readout of second messenger transduction is obtained. Such applications are well known in the art. However, mere exemplary applications of the present invention include but are not limited to:

-   -   a. Identifying test compounds that act as agonists, antagonists,         inverse agonists or natural ligands of cell surface receptor         selected from growth factors, cytokines, G-protein coupled         receptors, integrins and calcium ion channels by studying the         second messenger movement using fluorescence microscopy devices.         In a preferred embodiment, said cell surface receptor is a         G-protein coupled receptor (GPCR).     -   b. Expression cloning of peptide agonist, antagonist and inverse         agonist of receptors.     -   c. Expression cloning of modulators that change the second         messenger intracellular presence.     -   d. Establishing dose-response curves of membrane molecules         modulators.     -   e. Determining alterations in membrane molecules and modulators         involved in a disease or disorder which signalling cascade         depends on these second messengers and thereby the biosensor can         be used as a diagnostic tool.

In a preferred embodiment of the invention, the fluorescent fusion polypeptide as defined in any of the first, second, third or fourth aspects of the invention or the biosensor as defined in the sixth aspect of the invention can be used to generate stable cell lines which allow studying G-protein coupled receptors (GPCR), ion channels, and the activity of others proteins in living cells. The rapid translocation of the biosensor of the invention allows the quantification of GPCR and ion channel stimulation.

The fluorescent fusion polypeptide and the corresponding biosensor of the present invention can be made by techniques well known by those skilled in the art but as a way of example, they can be constructed as follows. The coding sequences corresponding to the membrane localization peptide, the fluorescent peptide, the protein transduction interacting peptide and the reticulum localization signal can be easily amplified by PCR and cloned into a shuttle plasmid. These coding sequences can be then easily cloned into the final fusion plasmid in the specific order presented herein using the restriction enzyme sites that flanked each sequence.

The following examples merely serve to illustrate the present invention.

EXAMPLES Example 1. Construction and Use of a Calcium Biosensor for Measurement of Calcium in Living Cells within a Broad Dynamic Range of Physiological Concentrations of this Second Messenger

The authors of the present invention constructed a fluorescent fusion polypeptide comprising the extracellular domain of interleukin-2 receptor of SEQ ID No 17 as the membrane localization peptide, the calmodulin binding domain from muscle myosin light chain kinase of SEQ ID No 1 as the second messenger transduction protein binding peptide, the peptide KDEL as the reticulum retention signal and the turboGFP as the fluorescent peptide wherein:

-   -   a. the membrane localization peptide was located at the         N-terminus of the fluorescent fusion polypeptide and was         physically bound, through a linker, to the fluorescent peptide,         which in turn was physically bound, through a linker, to the         second messenger transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide was         physically bound, through a linker, to the reticulum retention         signal, which in turn is located at the C-terminus of the         fluorescent fusion polypeptide.

The complete fluorescent fusion polypeptide is illustrated in SEQ ID No 15.

In order to assess whether this polypeptide induces intracellular fluorescence redistribution in living cells, the turboGFP polypeptide was cloned as the fluorescent peptide and the cellular localization of the biosensor was analysed upon calcium induced activation. In this sense, cell lines HEK293 and U2O2 were stably transfected with the plasmid construction that contains the above mentioned biosensor's cDNA (please refer to SEQ ID No 15). After transfection, both cell lines presented a membrane distribution of the fluorescence. However, a substantial decrease in membrane distribution of the biosensor was observed after increasing the intracellular levels of calcium with 10 ng/ml of PMA and 1 uM of ionomycin. This result indicates that an increased in the concentration of intracellular calcium induces a conformational change in the biosensor which promotes a redistribution of the fluorescent biosensor. The activity was calculated as an increment of the granularity of these cells. These same results were obtained with three different clones of the above cell lines as illustrated in FIG. 2 (left graphic) which provides proof of the reproducibility of these results.

Secondly, in order to determine whether calcium induces a significant conformational change within a physiological dynamic range, the U2O2 biosensor stable cell line was stably transfected with the human Tachykinin receptor 1. The Tachykinin receptor 1 (TACR1) also known as Neurokinin 1 receptor (NK1R) or substance P receptor (SPR) is a G protein coupled receptor found in the central nervous system and peripheral nervous system. The endogenous ligand for this receptor is Substance P, although it has some affinity for other Tachykinins, Substance P is synthesized by neurons and transported to synaptic vesicles; the release of Substance P is accomplished through the depolarizing action of calcium-dependent mechanisms. When NK1 receptors are stimulated, they can generate various second messengers, which can trigger a wide range of effector mechanisms that regulate cellular excitability and function. One of these mechanisms leads to the mobilization of calcium from both intra- and extracellular sources.

The double stable cell line was seeded at 20,000 cells per well on 96-mm optical plates, and cultured in 200 ul of DMEM F12 supplemented with 10% fetal bovine serum. For fluorescent biosensor redistribution, cells were stimulated with different concentrations of the agonist Substancia P during 6 hours. After treatment, the nucleus was stained with DAPI and biosensor fluorescence redistribution was detected by fluorescence using image analysis algorithms. When cells were treated with the agonist, the biosensor was internalized from plasmatic membrane in high intensity vesicles (FIG. 3). The activity was calculated as an increment of the granularity of these cells. Cells were treated with 11 log dilution series (n=5). The Ec50 for the Substance P was ^(˜)9.5×10⁻¹² M after a treatment of 6 h with agonist. The redistribution assay was validated with an average of Z′=0.85+/−0.01 for High Content Screening (FIG. 4).

To check the biosensor sensibility in comparison with other methods, a typical fluorescent calcium assay was performed using Fura-2/AM ratiometric. Calcium increase inside the cell was measured using the ratio of the fluorescence from Fura2 bound and not bound to the ion. Cells were incubated with Fura2-AM and treated with increasing Substance P concentrations. Cells were treated with Substance P concentrations ranging from 0 to 10 μM by quadruplicate. The E_(C)50 for Substance P was ^(˜)1.4×10-8M. The calcium assay was validated with a Z′=0.84 for High Content Screening

In both quantification methods, the image acquisition was performed using a “BD Pathway 855” High-Content Bioimager from BD Biosciences.

Example 2. Construction and Use of a cAMP Biosensor for Measurement of cAMP in Living Cells within a Broad Dynamic Range of Physiological Concentrations of this Second Messenger

The authors of the present invention constructed a fluorescent fusion polypeptide comprising the extracellular domain of interleukin-2 receptor of SEQ ID No 17 as the membrane localization peptide, the protein kinase A (PKA) binding domain from A-kinase anchor protein (AKAP) of SEQ ID No 9 as the second messenger transduction protein binding peptide, the peptide KDEL as the reticulum retention signal and the turboGFP as the fluorescent peptide wherein:

-   -   a. the membrane localization peptide was located at the         N-terminus of the fluorescent fusion polypeptide and was         physically bound, through a linker, to the fluorescent peptide,         which in turn was physically bound, through a linker, to the         second messenger transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide was         physically bound, through a linker, to the reticulum retention         signal, which in turn is located at the C-terminus of the         fluorescent fusion polypeptide.

The complete fluorescent fusion polypeptide is illustrated in SEQ ID No 16.

As with the biosensor of Example 1, in order to assess whether the activation of the above mentioned polypeptide induces intracellular fluorescence redistribution in living cells, peptide turboGFP was cloned as the fluorescent peptide and the cellular localization of the biosensor was analysed upon cAMP induced activation. In this sense, cell lines SHSY5Y and U2O2 were stably transfected with the plasmid construction that contains the above mentioned biosensor's coding sequence. Both cell lines presented a membrane distribution of the fluorescence. As with Example 1, activity was calculated as an increment of granularity by treating these cells with 10 uM of forskolin and 25 uM of IBMX in three different stable clones during 36 h (FIG. 2 Right graphic).

To determine whether cAMP induces a significant conformational change within a physiological dynamic range, the U2O2 biosensor stable cell line was stably transfected with the human adrenergic beta 2 receptor. The adrenergic receptors are a class of G protein-coupled receptors that are targets of the catecholamines, especially noradrenaline (norepinephrine) and adrenaline (epinephrine). The double stable cell line was seeded at 20.000 cell per well on 96-mm optical plates, and cultured in 200 ul of DMEM F12 supplemented with 10% fetal bovine serum. For fluorescent biosensor redistribution, the cells were stimulated with different concentrations of Isoproterenol agonist during 36 hours (FIG. 5). After treatment, the nucleus was stained with DAPI and biosensor fluorescence redistribution was detected by fluorescence using image analysis algorithms. When cells were treated with the agonist, the biosensor was internalized from plasmatic membrane in high intensity vesicles. The activity was calculated as an increment of granularity these cells. Cells were treated with 11 log dilution series (n=5). The Ec50 for the Isoproterenol was ^(˜)2.3×10-7M after a treatment of 24 h with agonist. The redistribution assay was validated with an average of Z′=0.7+/−0.01 for High Content Screening. The results are shown in FIG. 6.

Example 3. Construction and Use of a Diacylglycerol Biosensor for Measurement of Diacylglycerol in Living Cells within a Broad Dynamic Range of Physiological Concentrations of this Second Messenger

The authors of the present invention constructed a fluorescent fusion polypeptide comprising the extracellular domain of interleukin-2 receptor of SEQ ID No 17 as the membrane localization peptide, the binding sequence of SEQ ID No 19 as the second messenger transduction protein binding peptide, the peptide KDEL as the reticulum retention signal and the turboGFP as the fluorescent peptide wherein:

-   -   a. the membrane localization peptide was located at the         N-terminus of the fluorescent fusion polypeptide and was         physically bound, through a linker, to the fluorescent peptide,         which in turn was physically bound, through a linker, to the         second messenger transduction protein binding peptide; and     -   b. the second messenger transduction protein binding peptide was         physically bound, through a linker, to the reticulum retention         signal, which in turn was located at the C-terminus of the         fluorescent fusion polypeptide.

The complete fluorescent fusion polypeptide is illustrated in SEQ ID No 18.

As with the previous examples, in order to assess whether the activation of the above mentioned polypeptide induces intracellular fluorescence redistribution in living cells, peptide turboGFP was cloned as the fluorescent peptide and the cellular localization of the biosensor was analysed upon diacylglycerol induced activation. In this sense, U2O2 cell line was stably transfected with the plasmid construction that contains the above mentioned biosensor's coding sequence. This stably transfected cell line presented a membrane distribution of the fluorescence before inducing the activation of intracellular diacylglycerol. As with the previous examples, activity was calculated as an increment of granularity by treating these cells with increasing dosages of PMA. The results are shown in FIG. 7 and FIG. 8.

SEQUENCE LISTING SEQ ID No 1: MEKRRWKKNFIAVSAANRFKKISSSGAL SEQ ID No 2: ASPWKSARLMVHTVATFNSI SEQ ID No 3: AIGFKKLAEAVKFSAKLMGQ SEQ ID No 4: KKTFKEVANAVKISASLMGT SEQ ID No 5: GAVLKVLTTGLPALISWIKR SEQ ID No 6: RGGFRRIARLVGVLREWAYR SEQ ID No 7: GGRLALLRARLKELAALEAA SEQ ID No 8: AEGVRNIKSMWEKGNVFSSP SEQ ID No 9: DLIEEAASRIVDAVIEQVKAAGAY SEQ ID no 10: VQGNTDEAQEELAWKIAKMIVSDVMQQ SEQ ID No 11: VQGNTDEAQEELLWKIAKMIVSDVMQQ SEQ ID No 12: FEELAWKIAKMIWSDVFQQ SEQ ID No 13: QIEYLAKQIVDNAIQQAK SEQ ID No 14: LEQYANQLADQIIKEATE SEQ ID No 15: MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWD NQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCV QGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATM ETSIFTTDLQVAVAGCVFLLISVLLLSGLTWQRRQRKSGRTIGIQLVVDQQQQQQGILQSTVPMESDESGLPAMEIECRIT GTLNGVEFELVGGGEGTPEQGRMTNKMKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYENPFLHAINNGGYTNTRIE KYEDGGVLHVSFSYRYEAGRVIGDFKVMGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNDLDGSFTRTFSLRDGGYYSSV VDSHMHFKSAIHPSILQNGGPMFAFRRVEEDHSNTELGIVEYQHAFKTPDADAGEERSREMEKRRWKKNFIAVSAANR FKKISSSGALKDEL SEQ ID No 16: MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWD NQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCV QGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATM ETSIFTTDLQVAVAGCVFLLISVLLLSGLTWQRRQRKSGRTIGIQLVVDQQQQQQGILQSTVPMESDESGLPAMEIECRIT GTLNGVEFELVGGGEGTPEQGRMTNKMKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYENPFLHAINNGGYTNTRIE KYEDGGVLHVSFSYRYEAGRVIGDFKVMGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNDLDGSFTRTFSLRDGGYYSSV VDSHMHFKSAIHPSILQNGGPMFAFRRVEEDHSNTELGIVEYQHAFKTPDADAGEERSRVDLIEEAASRIVDAVIEQVKA AGAYGGKDEL SEQ ID No 17: MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWD NQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCV QGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATM ETSIFTTDLQVAVAGCVFLLISVLLLSGLTWQRRQRKSGRTI SEQ ID No 18: MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGNSSHSSWD NQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQASLPGHCREPPPWENEATERIYHFVVGQMVYYQCV QGYRALHRGPAESVCKMTHGKTRWTQPQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATM ETSIFTTDLQVAVAGCVFLLISVLLLSGLTWQRRQRKSGRTIGIQLVVDQQQQQQGILQSTVPMESDESGLPAMEIECRIT GTLNGVEFELVGGGEGTPEQGRMTNKMKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYENPFLHAINNGGYTNTRIE KYEDGGVLHVSFSYRYEAGRVIGDFKVMGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNDLDGSFTRTFSLRDGGYYSSV VDSHMHFKSAIHPSILQNGGPMFAFRRVEEDHSNTELGIVEYQHAFKTPDADAGEERSRVAARKRKGSFFYGGKDEL SEQ ID No 19: AARKRKGSFFYGG SEQ ID No 20: MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGVQCFSRYPDHMK QHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQK NGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELY K SEQ ID No 21 MFKGIVEGIGIIEKIDIYTDLDKYAIRFPENMLNGIKKESSIMFNGCFLTVTSVNSNIVWFDIFEKEARKLDTFREYKVGDRV NLGTFPKFGAASGGHILSARISCVASIIEIIENEDYQQMWIQIPENFTEFLIDKDYIAVDGISLTIDTIKNNQFFISLPLKIAQN TNMKWRKKGDKVNVELSNKINANQCW SEQ ID No 22 MESDESGLPAMEIECRITGTLNGVEFELVGGGEGTPEQGRMTNKMKSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYE NPFLHAINNGGYTNTRIEKYEDGGVLHVSFSYRYEAGRVIGDFKVMGTGFPEDSVIFTDKIIRSNATVEHLHPMGDNDLD GSFTRTFSLRDGGYYSSVVDSHMHFKSAIHPSILQNGGPMFAFRRVEEDHSNTELGIVEYQHAFKTPDADAGEE SEQ ID No 23 MVSKGEELIKENMHMKLYMEGTVNNHHFKCTSEGEGKPYEGTQTMRIKVVEGGPLPFAFDILATSFMYGSRTFINHTQ GIPDFFKQSFPEGFTWERVTTYEDGGVLTATQDTSLQDGCLIYNVKIRGVNFPSNGPVMQKKTLGWEANTEMLYPADG GLEGRSDMALKLVGGGHLICNFKTTYRSKKPAKNLKMPGVYYVDHRLERIKEADKETYVEQHEVAVARYCDLPSKLGHK LN SEQ ID No 24 MVGEDSELITENMHMKLYMEGTVNNHHFKCTSEGEGKPYEGTQTMKIKVVEGGPLPFAFDILATSFMYGSKAFINHTQ GIPDFFKQSFPEGFTWERITTYEDGGVLTATQDTSLQNGCLIYNVKINGVNFPSNGPVMQKKTLGWEASTEMLYPADS GLRGHGQMALKLVGGGYLHCSLKTTYRSKKPAKNLKMPGFHFVDHRLERIKEADKETYVEQHEMAVAKYCDLPSKLGH S SEQ ID No 25 MSGGEELFAGIVPVLIELDGDVHGHKFSVRGEGEGDADYGKLEIKFICTTGKLPVPWPTLVTTLCYGIQCFARYPEHMKM NDFFKSAMPEGYIQERTIQFQDDGKYKTRGEVKFEGDTLVNRIELKGKDFKEDGNILGHKLEYSFNSHNVYIRPDKANNG LEANFKTRHNIEGGGVQLADHYQTNVPLGDGPVLIPINHYLSTQTKISKDRNEARDHMVLLESFSACCHTHGMDELYR 

1. A fluorescent fusion polypeptide, wherein said fluorescent fusion polypeptide is capable of changing its localization within a cell from cytoplasmic membrane to a retention vesicle upon an increase in the concentration of a second messenger in the cytoplasm of the cell, wherein the second messenger is diacylglycerol, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein: a. the membrane localization peptide is located at the N-terminus of the fluorescent fusion polypeptide and is physically bound to the fluorescent peptide, which, in turn, is physically bound to the second messenger transduction protein binding peptide; and b. the second messenger transduction protein binding peptide is physically bound to the reticulum retention signal, which, in turn, is located at the C-terminus of the fluorescent fusion polypeptide.
 2. The fluorescent fusion polypeptide of claim 1, wherein: a. the membrane localization peptide is the extracellular domain of interleukin-2 receptor of SEQ ID NO: 17 or a variant which is at least 90% homologous to this sequence over the entire region based on amino acid identity; and b. the reticulum retention signal is the peptide selected from the group consisting of KDEL, HDEL, KKXX, KXKXX and RXR, wherein X is any amino acid.
 3. The fluorescent fusion polypeptide of claim 1, wherein: a. the membrane localization peptide is the extracellular domain of interleukin-2 receptor of SEQ ID NO: 17; and b. the reticulum retention signal is the peptide KDEL.
 4. The fluorescent fusion polypeptide of claim 1, wherein the second messenger transduction protein binding peptide comprises a binding sequence to PKCδ.
 5. The fluorescent fusion polypeptide of claim 4, wherein the binding sequence to PKCδ is selected from the group consisting of SEQ ID NO: 19 and a variant thereof which is at least 90% homologous to SEQ ID NO: 19 over the entire region based on amino acid identity.
 6. The fluorescent fusion polypeptide of claim 4, wherein the reticulum retention signal is KDEL.
 7. The fluorescent fusion polypeptide of claim 4, wherein the membrane localization peptide is the extracellular domain of interleukin-2 receptor of SEQ ID NO:
 17. 8. The fluorescent fusion polypeptide of claim 4, wherein the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602.
 9. The fluorescent fusion polypeptide of claim 4, wherein: a. the second messenger transduction protein binding peptide comprises a binding sequence to PKCδ and is selected from the group consisting of SEQ ID NO: 19 and a variant thereof which is at least 90% homologous to SEQ ID NO: 19 over the entire region based on amino acid identity; b. the membrane localization peptide is the extracellular domain of interleukin-2 receptor of SEQ ID NO: 17; c. the fluorescent peptide is selected from the group consisting of GFP, YFP, turboGFP, tRFP and tRFP602; and d. the reticulum retention signal is KDEL.
 10. The fluorescent fusion polypeptide of claim 4, wherein said polypeptide comprises SEQ ID NO:
 18. 11. A nucleic acid molecule comprising a polynucleotide sequence coding for a fluorescent fusion polypeptide of claim
 1. 12. A biosensor comprising the fluorescent fusion polypeptide of claim
 1. 13. A cell comprising the fluorescent fusion polypeptide of claim
 1. 14. A cell comprising the biosensor of claim
 12. 15. A method for in vitro detection and/or quantification of second messengers in a cell, the method comprising transfecting said cell with a plasmid encoding the fluorescent fusion polypeptide of claim
 1. 